


**RECEIVED**  
**CENTRAL FAX CENTER****DEC 19 2006****Bristol-Myers Squibb Company**  
**Patent Department****FACSIMILE TRANSMISSION SHEET**

**DATE:** December 19, 2006

**TO:** USPTO

**FACSMILE NO:** 571-273-8300

**NUMBER OF PAGES:** 7 (including cover sheet)

**FROM:** Brian C. Carey, Esquire *BCC*

**COMPANY:** Bristol-Myers Squibb Company

**FACSIMILE NO.:** (609) 252-4526

**RE:** BMS Reference: D0295 NP  
US APPLICATION NO: 10/663,002  
Reply to First Office Action Under 37 CFR §1.111

If you do not receive all pages please contact  
Michelle King @ (609) 252-7687.

DEC. 19. 2006 11:30AM

BMS PATENT DEPT

**RECEIVED**  
**CENTRAL FAX CENTER**  
**DEC 19 2006**

NO. 6060 P. 2/7

CASE D0295 NP

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to 571-273-8300 the Patent and Trademark Office on the date shown below.

\_\_\_\_\_  
Brian C. Carey  
Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
December 19, 2006  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

Art Unit: 1636

MUKHERJEE ET AL

Examiner: DUNSTON, DR. JENNIFER A.

APPLICATION NO: 10/663,002

FILED: SEPTEMBER 16, 2003

FOR: ASSAY FOR PPAR LIGAND DEPENDENT GENE MODULATION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO FIRST OFFICE ACTION UNDER 37 CFR §1.111**

Sir:

This is in response to an Office Action dated September 19, 2006 which is due December 19, 2006, with a shortened statutory period for reply.

This Response is deemed to be timely filed. However, if any fee is deemed to be due, the Commissioner is hereby authorized to charge any fees or credit any overpayments to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

The listing of claims begins on page 2. Remarks begin on page 4.